The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer ...

The firm said it has received positive feedback from the FDA on the design of a Phase III trial of ELI-002 in KRAS-mutant pancreatic cancer.

Verastem Oncology (NASDAQ: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.

Below is a detailed analysis of the two drugs secured by Cosmos Health. Abstract #1: ESTERS OF STEROIDAL LACTAM AND BIS (2-CHLOROETHYL) AMINOPHENOXY PROPANOIC ACID DERIVATIVES; Patent International ...

在非小细胞肺癌中，KRAS基因突变的比例不是特别高，其中KRAS基因G12C突变在白种人突变的概率是10%，在亚裔患者的突变概率是3%。经过数十年的研究，针对KRAS基因G12C目前已经有了靶向药，Sotorasib（中文翻译为：索托拉西布）是一种口 ...

Fred Hutch scientist rapidly reduces lung tumors in mice with a tagging system that grabs cancer-causing proteins and hauls them out.

Son of sevenless homolog 1 (SOS1) is an essential guanine nucleotide exchange factor (GEF) in KRAS-driven tumors, and it also functions as a downstream node protein of BCR-ABL, suggesting its critical ...

Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...

The global AI in oncology market, valued at US$1.92 billion in 2023, is forecasted to grow at a robust CAGR of 29.4%, ...

Amgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA for treating KRAS G12C-mutated mCRC.